OncoStem is an oncology diagnostic focussed startup companywith the vision of developing novel diagnostic tests to predict ‘cancer recurrence’, an area of huge unmet medical need. OncoStem’s initial focus is breast cancer as it is the most common cancer in women across the globe. In India, currently there are no tests to ‘predict’ risk of cancer recurring, thus 95% of patients get over treated with CT/RTwhich reduces ‘quality of life’ and is a monetary drain.Affordable and broadly distributed tests to estimate the ‘risk of recurrence’ are an absolute necessity for ‘optimum’ treatment planning and to avoid unnecessary side effects.

OncoStem has developed and validated its flagship product “CanAssist-Breast”, a unique panel of ‘prognostic and predictive’ proteomic markers that is indicative of the aggressiveness of cancer. CanAssist-Breast is a robust, cost effective, ‘Morphometric ImmunoHistoChemistry’ (mIHC) based test which can predict ‘risk of cancer recurrence’ for HR-positive breast cancer patients in Stage 1-2 using a Statistical algorithm.This breast cancer recurrence diagnostic is the first of many such tests in development across several cancer types and is designed to predict the patients’ risk of cancer recurrence within the first five years of their initial diagnosis, based on the characteristics of their tumor sample. This will in-turn allow optimal & personalized treatment planning for each patient so that risk of such recurrence is minimized. CanAssist-Breast is scheduled to be launched by June, 2016.OncoStem also plans to develop similar tests for other cancers such as oral, glioma, lung and colon.

OncoStem Diagnostics Pvt Ltd at MSCTR

  • Developing novel prognostic and predictive multigene qRT-PCR based test for assessing risk of recurrence on stage I-III A breast cancer patients
  • Cell based assays towards development of novel targeted drugs